Illumina, Inc. (ILMN) Earnings Call Transcript & Summary

February 8, 2024

NASDAQ US Health Care Life Sciences Tools and Services earnings 61 min

Earnings Call Speaker Segments

Sallilyn Schwartz

executive
#1

Hello, everyone, and thanks for being with us on this call about our fourth-quarter and full-year 2023 results. We'll review the financial figures we released after the market closed today, then share some thoughts on our commercial and regulatory efforts, and after that we'll take your questions. Our earnings release is available on the Investor Relations page of illumina.com. With us from Illumina are Jacob Thaysen, our Chief Executive Officer, and Joydeep Goswami, Chief Financial Officer and Chief Strategy and Corporate Development Officer. Jacob will provide an update on where Illumina's business stands, and Joydeep will cover our financial results, including GRAIL. Just as a reminder, the European Commission's transitional measures—which barred our purchase of GRAIL under the EU merger regulation—require GRAIL to be kept and run separately and independently from Illumina. This call is being recorded, and the audio portion will be archived in the Investors section of our website. We intend for all forward-looking statements about our financial results and commercial activity made during today's call to be protected under the Private Securities Litigation Reform Act of 1995. Forward-looking statements carry risks and uncertainties. What we project or discuss could end up differing significantly from what actually happens. Every forward-looking statement reflects only the information available right now, and Illumina takes on no duty to revise those statements later. For a clearer picture of the risks and uncertainties that might make real outcomes diverge, please review the filings Illumina makes with the Securities and Exchange Commission, among them its latest Forms 10-Q and 10-K. On that note, I'll pass things over to Jacob now.

Jacob Thaysen

executive
#2

Thanks, Salli. Good afternoon, everyone. As you know, I came on board as Illumina's CEO just over 4 months ago. During that stretch, one of my priorities has been sitting down with customers—learning what matters most to them, listening to what they have to say, and building relationships that feel more like a partnership. Our customers hold Illumina and our solutions in high regard, and they're eager to team up with us strategically to push the entire NGS ecosystem ahead. With the GRAIL divestiture now announced, it's become simpler for our customers to map out what their future with Illumina will look like; these conversations have been both educational and motivating. On a recent visit to Europe, I got to observe directly the ways we collaborate with customers, governments, and the wider genomics community to speed up whole genome sequencing adoption in a safe and more effective manner, and to comprehend rare diseases and cancers within the standard of care. I also gained knowledge about a German model project that intends to completely incorporate comprehensive genomic testing into that country's health care system starting in Q2 of this year. Additionally, both in the corridors of our headquarters and at a number of global offices, I have been meeting with our skilled staff members, who are devoted to propelling innovation and to further developing the genomics ecosystem. I've also been able to meet with a lot of you at investor conferences recently. What I'm hearing in those discussions is shaping the priorities I've set for my leadership, and importantly, it has strengthened how confident I feel about Illumina's core business. For Illumina, 2023 was a year full of change. NovaSeq X ranks as the most successful launch of a high-throughput product in the company's history. We closed out the year having shipped 352 NovaSeq X units, which came in above the 330 to 340 we had anticipated, even as the macroeconomic environment stayed difficult and we observed that many of our customers continued to hold back in their purchasing decisions; during the fourth quarter, consolidated revenue came in higher than expected at roughly $1.12 billion. Revenue in the Americas, which accounts for over half of our business, was flat compared with the same period a year earlier. Europe posted a 17% increase versus the prior year, helped by a fairly soft comparison. In EMEA, revenue fell 1%, a figure that reflects a 10 percentage point hit from Russian sanctions. Greater China saw a 13% year-on-year decline, driven by ongoing geopolitical difficulties and local rivals in mid-throughput. As I've said previously, China and the customers we serve there matter greatly to Illumina. We have already implemented some pricing and other strategic measures, and those are starting to produce results. We'll provide further details about our progress in that market in due course. Around the world, we anticipate customers will stay cautious. At this point, we still expect 2024 to come in much like 2023. Although certain macroeconomic indicators look positive, that improvement has not yet shown up as greater spending within our sector—so we have not built it into our guidance. In a few minutes, Joydeep will walk you through the specifics of that guidance. The outside environment is beyond our control, but the management team and I stay focused on speeding up value creation throughout the company. As you are aware, I have laid out three main priorities that I believe will position Illumina for quicker growth and stronger profitability once market conditions improve. The first priority involves growing our top line—this means continually expanding our installed base and assisting customers in getting more out of these instruments, whether in new applications or existing ones. As I noted before, we're really pleased with how the inaugural year of NovaSeq X shipments went. When you look at high throughput on a wider basis — NovaSeq X and NovaSeq 6000 taken together — we installed over 400 instruments during 2023. In 2024, we'll support that growing installed base as customers kick off large projects and more sequencing-intensive applications such as multiomics, liquid biopsy and minimal residual disease, or MRD; we expect high throughput instrument orders to keep coming throughout 2024, mainly from additional conversion of NovaSeq 6000 customers to the X, from expansions of customer fleets and, over the long term, from customers new to high throughput; that said, because of the significant number of placements in 2023, we think we'll ultimately move fewer high-throughput instruments in 2024. As you're aware, XLEAP-SBS chemistry has powered our X platform, delivering meaningful gains in quality, turnaround time and cost. During this quarter, we will bring XLEAP to mid-throughput clients using their current NextSeq 1000 and 2000 machines, with no instrument upgrade needed. This move reinforces our global leadership and advances fields like single cell, spatial, and proteomics. While expanding the installed base, our attention remains on helping customers kick off new projects. That should fuel consumables demand both this year and beyond. Demand-building work is already delivering results. In Q4, ex consumable sales grew more than we anticipated after our highly awaited 25B rating kit launched in late October. Then, more recently in January, we brought out a 1.5B kit. Combined with the 25B and 10B flow cells, this enables us to provide NovaSeq X customers with a complete product lineup. We'll keep seeing customers work down their NovaSeq 6000 consumable inventories as they move over to the X, but as we build pull-through on the NovaSeq X, that will fuel growth in our high throughput consumables overall this year. Now for my second priority. My focus is on operational excellence — bringing more rigor across our entire P&L while still sustaining innovation and growth. We've started a multiyear push aimed at boosting our margins by raising productivity and finding more places to cut costs; in January, we took one more step to further streamline our worldwide workforce. Across the past year, role eliminations have added up to roughly 12%. The latest moves we made included an adjustment that we tied to the portfolio optimization work we did in late 2023. You'll see us keep taking steps both to control near-term costs and to build the agility needed to deliver stronger, more durable growth and margins over time. Illumina is following a highly disciplined strategy to support our customers, employees and partners and to generate returns for shareholders across a range of macroeconomic conditions. My third priority is getting GRAIL resolved as quickly as possible. Ever since I came to Illumina, I've treated swift action on GRAIL as a must. Back in December, we committed to divesting GRAIL and said we aimed to wrap up the deal's terms by the end of Q2 this year. We'll continue to advance both options simultaneously. The divestiture will happen through either a sale to a third party or a capital markets transaction, consistent with the European Commission's divestiture order. Thus far, we've made quick headway. A Form 10 for GRAIL has been confidentially filed with the SEC. Advisers are actively advancing the process along both the sale and capital market tracks. The Board's special committee, which we established in Q3, remains instrumental in helping ensure this effort moves forward efficiently. The momentum with which we have entered 2024 encourages me, and I am committed to seeing our initiative through to completion. At this point, I will turn things over to Joydeep for additional detail on our 2023 results and our 2024 outlook.

Joydeep Goswami

executive
#3

Thanks, Jacob. To begin, I'll go over the consolidated financial results, then the segment results for core Illumina and GRAIL, and finish with my comments about how 2024 is shaping up. My discussion will cover non-GAAP results, and those include stock-based compensation. Please take a look at the GAAP reconciliation for these non-GAAP measures; it's in today's release and in the supplementary data posted on our website. For the fourth quarter, consolidated revenue came to $1.12 billion, an increase of 4% versus a year ago, on a reported basis and in constant currency alike. Compared with the third quarter of 2023, consolidated revenue was flat. Non-GAAP net income totaled $22 million, or $0.14 per diluted share, and that figure reflected dilution from GRAIL's non-GAAP operating loss of $152 million during the quarter. Non-GAAP EPS came in above what we expected, thanks to higher revenue and gross margin as well as lower operating expense in the quarter. Our non-GAAP tax rate was 55.4% for the quarter and 41.8% for the full year 2023, versus 29.3% in Q4 2022 and 26% for the full year 2022. While R&D capitalization requirements affected both periods, the hit to our effective tax rate was larger in 2023 because our earnings were lower. On top of that, the non-GAAP tax rate in each year carries a sizable effect from consolidating GRAIL's losses. Without GRAIL, our core tax rate for the full year 2023 landed in the mid-20s. Our non-GAAP weighted average diluted share count for the quarter was roughly 159 million. Now on to segment results. Core Illumina fourth quarter revenue was $1.1 billion, up 3% from a year earlier on a reported basis and in constant currency, and it included an anticipated roughly 5 percentage point reduction from 2 main categories: first, the decline in COVID surveillance plus the effect of sanctions in Russia, which together accounted for about 3 percentage points, and second, the year-over-year drop in China revenue, which accounted for about 2 percentage points. Even with those impacts, core Illumina revenue beat expectations, helped by stronger-than-projected NovaSeq X placements and greater uptake of X consumables, with strong early demand for the 25B flow cell launched in Q4. Core Illumina sequencing consumables revenue was $687 million, flat versus a year ago. Stronger-than-expected NovaSeq X consumables purchases were mostly offset by the anticipated decline in NovaSeq 6000 consumables and by pricing transitions as customers keep adopting the NovaSeq X. Total sequencing consumables revenue was also affected by the COVID, Russia and China factors I mentioned earlier, along with ongoing macroeconomic pressure on how customers purchase. COVID surveillance added approximately $4 million in total revenue in Q4 2023, compared with $20 million in Q4 2022. Turning to sequencing activity, total activity on our connected high and mid-throughput instruments rose 46% year-over-year in the quarter, after the 29% year-over-year growth we reported in Q3. On a sequential basis, Q4 sequencing activity was up 13% from Q3. To give you some context, we view these figures as a helpful benchmark illustrating overall activity patterns throughout our installed base, and they tend to correlate directionally with revenue as time goes on. Sequencing instruments revenue for core Illumina came to $161 million, up 10% year-over-year in Q4, mostly on the strength of NovaSeq X, which more than made up for fewer NovaSeq 6000 shipments. Gains in high-throughput instruments were partly offset by the anticipated drop in mid- and low-throughput shipments, reflecting capital purchase and cash flow constraints that keep weighing on how our customers buy, along with local competition in China. On NovaSeq X, we finished Q4 with 390 orders since launch. We shipped 79 NovaSeq X instruments during Q4, which lifted our total installed base to 352 instruments. Although we anticipate that most NovaSeq 6000 customers will move to NovaSeq X eventually, this transition remains at a very early stage. At the close of 2023, our net installed base for NovaSeq 6000 stood at roughly 1,770 instruments, a figure that reflects about 110 instruments deactivated between 2017 and 2023. Most of those occurred in 2023 as customers transitioned to NovaSeq X; we anticipate that number will rise in 2024 as customers keep ramping up utilization of NovaSeq X. Also, starting going forward, we will report annual instrument installed base figures on a net basis, meaning we account for instruments decommissioned or inactivated since launch. The information on this slide contains further details to assist you with your modeling. We will post this presentation on our Investor Relations website after our prepared remarks. Core Illumina sequencing service and other revenue totaled $152 million, an increase of 16% year-over-year, mainly driven by higher revenue from strategic partnerships and greater instrument service contract revenue on a growing installed base. Turning to the remainder of the core Illumina P&L. Core Illumina non-GAAP gross margin for the quarter was 64.7%, a decrease of 260 basis points year-over-year, mainly due to the mix of lower-margin strategic partnership revenue, lower instrument margins stemming from the NovaSeq X launch, which is typical when introducing a new platform, and higher field services and installation costs, partly offset by lower freight costs. Core Illumina non-GAAP operating expenses were $507 million, down $21 million year-over-year, largely because of ongoing expense reduction initiatives and lower performance-based stock compensation expense year-over-year. Given these factors and higher revenue, core Illumina non-GAAP operating margin came in at 18.5% in Q4 2023, compared with 17.8% in Q4 2022. Now moving to financial results for GRAIL. GRAIL revenue for the quarter was $30 million, up 30% year-over-year, primarily driven by adoption of Galleri. GRAIL non-GAAP operating expenses came to $167 million, an increase of $1 million year-over-year. Turning to consolidated cash flow and balance sheet items for the quarter. Cash flow provided by operations was $224 million. Capital expenditures were $51 million, and free cash flow was $173 million. No shares of our common stock were bought back, and we closed the quarter holding roughly $1.05 billion across cash, cash equivalents and short-term investments. Turning to our 2024 guidance: with Illumina working as fast as it can to resolve GRAIL, and given uncertainty about precisely when the GRAIL divestment will occur and what its impact will be, the company's 2024 financial outlook centers on core Illumina. Our guidance builds in no effect from a possible GRAIL divestment during 2024. Once the divestment closes, we will give non-GAAP EPS guidance covering the whole of 2024. As Jacob said, our outlook presumes the current difficult macroeconomic backdrop carries on through 2024, and that tighter funding and budget pressures keep weighing on our customers' purchasing decisions. For the full year 2024, we expect core revenue to be roughly flat versus 2023, which reflects these offsetting factors. Core Illumina sequencing instrument revenue, we expect, will fall in the high teens compared with the prior year, driven mainly by fewer NovaSeq X instrument placements. That reduction reflects the anticipated shift in our adoption curve toward early majority customers from early adopters, plus the lower backlog we carry into 2024 relative to 2023. We further expect capital and cash flow constraints to keep affecting purchasing behavior and to temper instrument placements in 2024.

Joydeep Goswami

executive
#4

When it comes to core Illumina sequencing consumables revenue, our expectation is growth in the low single digits versus the prior year. The primary factor behind that is modest expansion in high-throughput consumables, because greater purchases of NovaSeq X consumables along with sequencing volume ought to more than make up for the expected decline in NovaSeq 6000 consumables as well as the impact of pricing transitions. Moving now to annual pull-through: going forward, pull-through figures will be calculated and reported by us based on the net installed base of the instruments. As mentioned earlier, supplemental information to help with modeling appears in our earnings presentation, and following our prepared remarks it will be posted on our Investor Relations website. It is important to note that reported revenue is in no way impacted by this. On NovaSeq 6000, our expectation for 2024 is annual pull-through of about $700,000 to $800,000 per system, since customers continue shifting sequencing volume onto NovaSeq X. On NextSeq 1000 and 2000, we anticipate yearly pull-through between $80,000 and $130,000 per system in 2024, largely reflecting customers moving to X lead chemistry as it becomes available on NextSeq 1000 and 2000; for MiSeq, we expect annual pull-through of $30,000 to $40,000. Our remaining pull-through ranges should align with historical guidance; for core Illumina total sequencing revenue, we anticipate results roughly flat versus a year ago. That figure includes roughly $30 million in intercompany sales to GRAIL, which are removed during consolidation. For core Illumina, we anticipate a non-GAAP operating margin of about 20%. Our margin outlook accounts for gains from ongoing improvements in gross margin and cost-cutting efforts, which are partly offset by performance-based compensation returning to normal levels, along with inflation and market-driven merit raises. Core Illumina revenue for Q1 2024 is expected to come in between $1.03 billion and $1.04 billion, representing a decline of 3.5% to 4.5% compared with the prior year, primarily due to the factors that follow. For NovaSeq X instruments, we anticipate fewer shipments this year than last, since our backlog going into 2024 is smaller than the substantial preorder book we had entering 2023 after NovaSeq X launched. We anticipate that the year-over-year growth in NovaSeq X consumables purchases will be mostly offset by the expected decline in NovaSeq 6000 consumables along with pricing transition effects, which matches the pattern observed in Q4. Sequencing service and other revenue should rise compared with last year, powered by strategic partnership initiatives and greater instrument service contract revenue from an expanding installed base. Core Illumina non-GAAP operating margin for the first quarter is expected to come in at roughly 18%. Wrapping up with guidance for Q1: core Illumina's non-GAAP net other expense should land near $12 million. The rise compared with a year earlier stems mainly from reduced interest income, since our cash balance is smaller after we paid off the convertible notes in mid-2023. With that, I'll hand things back to Jacob for his closing remarks. Thanks.

Jacob Thaysen

executive
#5

Thank you, Joydeep. Before we wrap up and begin the Q&A, I'd like to talk about what I see as success, for this year as well as for the years to come. There's a real opportunity for Illumina to push the next-generation sequencing ecosystem ahead. We're going to strengthen ties with our customers and look for more ways to work together and partner with them so that NGS adoption grows further. What we aim for is making our customers the heroes in their own labs and backing them as they broaden their genomics and multiomics work. That, in turn, will help us capitalize on our market-leading innovation, keep Illumina differentiated, and hold on to our industry-leading position across research and clinical markets. We'll keep driving innovation centered on what matters most to our customers too. That means advancing our sequencing platform and providing stronger sample-to-answer solutions. There's room to integrate customers' workflows even more, which builds our share of wallet while creating more value for them. Our comprehensive strategy work is already well underway, and we'll share more with you later this year. I'm excited to be part of Illumina's leadership team that is driving our unmatched core business forward. Thank you for joining. I'll now invite the operator to open the line for Q&A.

Doug Schenkel

analyst
#6

I'd like to focus on the 25B chip release and what you're observing in the field as we head into the early part of the year. As you're aware, 25B brings the cost per genome down to roughly $200, but it also means customers need sufficient samples to run in order to fully consume the flow cells; so what have — what have you observed during the first few months of availability? What's the spending on X consumables? How did that compare with Q3? And do you see signs in the field that sample access isn't a problem as folks transition to the 25B?

Jacob Thaysen

executive
#7

Thanks, Doug. And that was a nice single question there; so let me begin by saying we've been quite pleased with the uptake of the 25B since it launched in late November. In fact, it has somewhat exceeded our expectations and has been very well received by customers; so we continue to expect that this will keep really driving X performance, but also, of course, it has now completely unlocked the full performance of the instrument, and as a result, we also expect that the 25B — that the availability of the 25B will bring more customers to jump onto the X wagon here. I think we are seeing customers being able to load it. Of course, many of them are still doing validation work, but we are seeing that they have projects big enough to load the flow cells.

Joydeep Goswami

executive
#8

Yes. And perhaps just one fast thing to add, correct? Roughly 40% of our X customers up to now have taken up the 25B.

Jacob Thaysen

executive
#9

That's right.

Puneet Souda

analyst
#10

Let me follow up on that. I mean, help us understand how you arrive at low single-digit growth this year. Obviously there's 25B. There are reductions happening — from just the X installs. Cost per database is lower. China remains challenging, and the market backdrop is challenging as well; so maybe talk us through a little about how you stay confident in that low single-digit sequencing consumable growth rate? And I'd really appreciate some context and details around GRAIL too. What progress has been made? What level of interest are you seeing? And what are you contemplating for spend on GRAIL this year?

Jacob Thaysen

executive
#11

All right. Thanks for that, Puneet; let me begin with the latter part of your question about GRAIL, and then I'll have Joydeep weigh in on our expectations here for consumables growth. But as I said, we're very pleased with the announcement we made in December that we are now divesting GRAIL for sure, and I'm actually very pleased with the progress so far; our advisers are really moving ahead and are now in connection and in conversations with the relevant parties. We're continuing to run a dual track, of course, via a capital market initiative or it can be a transaction. And so we still expect to stay on track with the time line. We previously talked about having — we will have all the terms finalized by end of Q2. So we are — at this point, we're not talking about — since we expect to finish up with GRAIL this year, we're not providing any guidance on the expenditure for GRAIL this year.

Joydeep Goswami

executive
#12

Absolutely. On your question about low single-digit consumables growth, Puneet — first, the traction we saw in Q4 with the 25B and 10B flow cells was really encouraging, and we're also pleased with that elasticity, where growth in underlying sequencing activity is being driven by X customers, right? So both of those are good. That rise in sequencing activity has now appeared for a second consecutive quarter. So again, it's broad-based. It spans both research and clinical customers; and the growth is present quarter-on-quarter and year-on-year. What's counterbalancing the growth we expect in X consumables — as you correctly noted — is the price transition we anticipate as customers shift from the NovaSeq 6000 over to the X. That's quite comparable to the price transition observed during the move from HiSeq to 6000, along with, of course, some anticipated decline in 6000 consumables as customers migrate between the two platforms, correct? So those factors — that's really the major element behind the lower — or the low single-digit growth rate for consumables in 2024.

Vijay Kumar

analyst
#13

My question about GRAIL has two parts. I realize the S-1 was filed confidentially. At what point does it become publicly available? The reason I'm asking is that GRAIL had operating losses of $700 million last year; it's genuinely difficult to imagine a capital markets deal happening with spending at those levels, so I'm quite eager to learn what assumptions the S-1 makes about GRAIL. Turning to consumable pull-through, $700,000 to $800,000 on NovaSeq 6000, Joydeep, is there something like a cadence, perhaps Q1, where we begin at the low end? And should we assume we finish Q4 at the top of that range?

Jacob Thaysen

executive
#14

Yes; let's begin with the GRAIL question. And clearly, we want to give all of you as much information as we can. At present, as you noted, the filing is confidential, and my expectation is that it won't be publicly available until very late in Q1, possibly spilling into Q2; so that's the situation as I see it. But the moment it becomes available, we'll be sure to let you know.

Joydeep Goswami

executive
#15

And then, Vijay, I want to make sure I’ve got this right. You’re asking about the NextSeq 6000 — sorry, the NovaSeq 6000 pull-through figures, and how those shift across the year?

Vijay Kumar

analyst
#16

Right, Joydeep. Are we assuming we begin at the bottom of that range and finish the year at the top end or above it?

Joydeep Goswami

executive
#17

No, we aren't. Again, pull-through, I want to stress once more, is a computed figure, so it's really the overall quantity of consumables sold during any quarter divided by the count of the currently active installed base for that quarter, correct? And we make no assumption regarding how that is spread across quarters.

Dan Arias

analyst
#18

Jacob or Joydeep, on the move from the 6000 to X and thinking about the clinical side — a large share of that bucket is those commercial labs that watch their own margins closely and want ways to get more efficient. So does it feel to you like X adoption could come faster than it would in a normal environment, so those folks can capture the cost savings? They seem to have an incentive for that, though I also know the clinical wheel turns slowly. So I'm just not certain whether that's a factor for them.

Jacob Thaysen

executive
#19

Yes. Of course, that's a pertinent hypothesis to bring in. What we've seen is that most of our clinical customers are using the chance that X's lower cost gives them to actually expand sequencing depth, offering larger panels and so on; so what we're seeing is that most of the current panels keep running on the NovaSeq 6000 and therefore keep driving volume there as well. And then they are, right now, validating many of the new assays — or the new assays that might not have been possible on the 6000 because of cost and so on — to be on the X. So we're quite encouraged about that; we've also seen several of our specialty labs customers now order tens of NovaSeq X; so I'm encouraged that we will see a lot of volume here going forward on this, including a $1.03 million contribution.

Subhalaxmi Nambi

analyst
#20

In 2022, you spent roughly $1 billion on R&D compared with 2019. Revenue grew at a 6% CAGR, but R&D grew at a 12% CAGR. Why is it not possible to cut R&D spending in dollar terms from where it stands now over the coming 1 or 2 years? Could you lay out how that spending is being allocated?

Jacob Thaysen

executive
#21

Yes, thank you. You're correct that we still think a great deal of innovation is needed, and so investment in R&D is necessary to move the entire NGS ecosystem ahead. We — as I mentioned, one of the things — what I said before is that one of the things I'm truly enthusiastic about is the innovation pipeline we currently have running, and because of that, plenty of innovation will also emerge from Illumina over the coming period. And we still think we're at an early stage of all the opportunities here in NGS, and in multiomics as well, and so we keep investing in that. You're also correct that R&D has risen, and we are definitely aiming to alter that trajectory as time goes on. We still think a high level of investment is necessary, but over the coming years you will see that R&D spending as a percentage of revenue begins to decline.

Joydeep Goswami

executive
#22

I’d also add, Subha, that over the past year we’ve made cuts in R&D. Those cuts have been quite deliberate, targeting particular parts of the portfolio that we saw as having payoff periods that were long — very long — or that carried more risk. On top of that, our total R&D encompasses spending in some areas, such as medical affairs and similar functions, that we had been carrying out to support customers. And now that those areas have matured, we’ve been in a position to scale back investment there while innovation remains unaffected.

Mason Carrico

analyst
#23

Now, regarding those high-throughput customers who've already bought an X — could you discuss what you're hearing from them about possibly expanding their fleets? Specifically, what share of those opportunities, whether we're talking orders or shipments, has already materialized, and how much of that opportunity is still left for this year?

Jacob Thaysen

executive
#24

Yeah. I'd say we're definitely seeing plenty of our high-end, high-volume customers — the ones who initially bought 1 or 2 NovaSeq X — beginning to think about picking up additional instruments. So they're using those first few X units to validate assays. After that, they want to expand — to use the extra Xs for actual production runs. But only a small number of customers have moved into production mode yet, and because of that, a genuinely large opportunity lies ahead of us. I believe fewer than half of our high-volume customers have bought an X to date, so plenty of opportunities remain, in my view. That said, as was mentioned earlier, some high-volume customers who bought 1 or 2 have now placed orders for 10 instruments. So we're clearly still at a very early stage, and there ought to be substantial opportunities ahead, in both '24 and '25, to drive additional placements.

Joydeep Goswami

executive
#25

Yeah, I'd just add that we hadn't anticipated seeing that ahead of the 25B flow cell launch, correct? So you're really at a very early stage there, and we do expect those fleet expansions to come through during this year.

David Westenberg

analyst
#26

I'd like to dig into some of the competitive offerings that are entering the space. At AGBT, for instance, we saw a few different things, including spatial and sequencing combined on a single platform. How do you think that stacks up competitively? Would you go after a strategy like that? Then, on Ultima and the $100 genome, some of the specs appear considerably stronger than they did a couple of years back. With some of your key bells and whistles, how do you feel you stack up against that $100 price point?

Jacob Thaysen

executive
#27

Yes. Thanks, Dave. And naturally, we're keeping tabs on everything happening in the market, and we take our competition very seriously. You've probably also picked up on my comments regarding multiomics. I believe I've mentioned multiomics to you several times, so we do have an intention to participate in that area. At this point, we're discussing taking a first step forward in proteomics through our partnerships with SomaLogic, but I think it's clear that—in fact, we believe there are many additional modalities that could be offered on the instruments. So regarding where Illumina is pursuing this, we'll come forward and share that insight once we're ready to bring something to market, and we'll say less about it while it remains further out in the future. Next, with NovaSeq X, we believe we're offering a highly compelling price point across a wide range of applications rather than just a handful. So our sense is that this is a very strong solution. That said, I'd also point out that cost per sequencing run is no longer the only relevant factor — you have to consider the expense of the entire workflow, including the number of manual steps involved, how much waste there is, instrument spending, and so forth. So I think that once you examine the specifics, you'll see that Illumina's platform is genuinely appealing and clearly differentiated.

Conor McNamara

analyst
#28

I just have a question about margins from a financial perspective. Your guidance is 18% for Q1 and 20% for the full year. So how should we think about the cadence of margin progression? And I suppose the same question applies to the tax rate. You mentioned a mid-20s figure for the core Illumina tax rate. How should we think about that in '24?

Joydeep Goswami

executive
#29

Yes. So the tax rate, once again, is something that should be — you should expect it to stay fairly constant as you go into — and again, for core Illumina into 2024. And this is core Illumina again, correct? We aren't yet providing guidance this year on the consolidated number. Regarding the operating margin cadence, again, that is — typically, it does rise as gross margins tend to rise as we move into greater volume and — through the year; on operating margin, you will see a decrease in — potentially in Q2 as merit and the other inflation-related aspects come into play. But after that, you will see a quarter-on-quarter increase as we move into the rest of the year. And then, of course, I think on the — sorry, just one other thing, right? I know there's been some movement on the R&D capitalization piece, but that is something we're watching very carefully. It has passed the House, but it still needs to get through the Senate and the President signing. If we get that, you can expect a further improvement in the tax rate, right? But we are not building that into our assumptions at this point.

Sung Ji Nam

analyst
#30

Regarding the MRD assay we're developing with Janssen, could you say whether it uses a tumor-informed or tumor-naive approach, or is it something else entirely? And is there a chance that this could eventually be developed into an IBD assay for clinical applications?

Joydeep Goswami

executive
#31

Yes. Thanks for asking. So to remind everyone again, what Illumina brings here is fairly distinctive. This is an MRD assay built on whole-genome sequencing; at first it's tumor-informed, yet with additional data behind it, there's potential to eventually shift to a tumor-naive approach, correct? As for whether it can be IBD, of course, as you're aware, we've put very substantial investment into platforms, technologies, and infrastructure that let us convert assays to IBD at the appropriate moment, right? So at present, our agreement with pharma has mostly been about exploring this in various forms; but we can make the move to IBD when the timing is right.

Jacob Thaysen

executive
#32

I should also mention that we don't plan to offer that via a CLIA lab — a commercial CLIA lab. We do have our own CLIA lab, which naturally is running very few samples, but we aren't going out to commercialize it through our CLIA lab. As a matter of fact, we're quite keen to collaborate with customers and partners so we can keep developing this.

Patrick Donnelly

analyst
#33

Joydeep, perhaps a quick question for you, and the follow-up is probably more directed at Jacob. But regarding the gross margin item, could you discuss a slight step down in 4Q—it came in a bit below where we had been expecting. Could you just address anything that had an effect on that during 4Q, and the right way to think about how it progresses through '24? And then on gross margin and pricing initiatives, Jacob, how are you approaching the price side? Again, I know somebody brought up AGBT. Competitors are making noise, essentially saying discounting is being seen in the market, particularly on the mid-throughput side. So I'm just curious, since you've had a look here, what your thinking is regarding pricing.

Joydeep Goswami

executive
#34

Yes. So Patrick, as for the sequential decline in gross margin during the fourth quarter, several factors are at play there, correct? First, revenue was lower, so obviously that has an effect in terms of fixed cost absorption alone. We also had an X contribution that was higher than expected; and that, combined with a greater amount of partnership revenue, which tends to carry lower margins, all impacted our gross margin figures. And then finally, I would note there was a mix shift away from 6000 consumables toward X consumables, and that too affected our overall gross margin number for Q4. I would say—and I think this leads into your question for Jacob—we achieved a great deal of progress during 2023 on COGS productivity, and we began to see the benefits of that as we moved out of 2023 and into 2024 as well and beyond.

Jacob Thaysen

executive
#35

Yes. If I — when — I came into this company, Patrick, and I looked at pricing and how we’re thinking about pricing going forward, first I’ll say that Illumina is offering a premium product, and because of that, I think our customers also see that we’re able to command premium pricing in the industry. But I think more importantly, talking only about cost per gigabase is probably too simplistic for most of our customers. They care more about the cost of the whole sample-to-insight process, the whole workflows; and that, of course, includes sample prep automation but probably even more importantly, informatics, which is also a key cost driver for our customers. So really, with the DRAGEN platform and what we have in our comprehensive informatics offering, we actually can give the customer a very cost-attractive solution; so therefore, just talking about cost per gigabase is kind of the — maybe the old way of looking at it, and the future way we look at it is a little more comprehensive; so I feel really good about that, where we are. And that said, we will now, with — in the mid-throughput, with the XLEAP-SBS chemistry becoming available, we are coming out with more attractive pricing, quality and more capacity on our 1000 and 2000 instruments; so I’m really excited about that and again, driving elasticity based on that new price point. So you will see us really move the knots on many more elements, not just one pricing element.

Eve Burstein

analyst
#36

I had a — I wanted to ask about where NextSeq stands; so you finished the year at 885 placements, and that's comfortably above your pre-pandemic level, but it's also under where you've sat for the last 2 years. So how much of that do you put down to simply shifting needs, obviously, post-pandemic? How much do you put down to the capital purchase and cash flow constraints you mentioned? And how much do you put down to competitive dynamics, which you also mentioned? And then how should we think about what normalized demand here looks like going forward?

Joydeep Goswami

executive
#37

Yes. So I think the major factors I would put at 2, maybe 3, right? There's also a secondary element here. The main drivers, as you correctly noted, were that coming out of COVID during '21 and '22, we saw a genuine surge in sales of mid-throughput and low-throughput instruments, correct? That has since settled down somewhat as the COVID threat has, thankfully, diminished; at the same time, in 2023 we also observed certain macroeconomic conditions that made our customers more cautious, and that greater caution showed up in capital purchases. The third driver, particularly for mid-throughput, was China as well, right? Looking at the total figure, China did take a hit from both competition and macro conditions, which is something we've said repeatedly on our 2023 earnings calls. On the competition side, it clearly played a role in China, though it doesn't appear to be a major factor elsewhere in the world, correct? We also monitor our competitive win rates quite closely, and we saw them level off in Q3 and Q4.

Dan Brennan

analyst
#38

Regarding the X pull-through, we were approaching roughly $1 million during the fourth quarter, and doing a bit of quick arithmetic, we figured it might land around $850,000 for 2024. So could you comment on whether those figures look reasonable? And if they do, would you mind explaining what would underpin the assumption behind that sort of sequential decline?

Jacob Thaysen

executive
#39

Thanks, Dan. Honestly, I think you've run more numbers on that than we have so far, since it's still very early — we're in the early innings when it comes to examining pull-through from the X. So we really haven't worked through that math yet, and we'll share those calculations once we believe we're in a steadier position where doing so makes sense. Any other thoughts on that, Joydeep?

Joydeep Goswami

executive
#40

No. Let me go back over that — look, it's still early. Jacob said before, I think, that a lot of customers are only now working through validation, particularly on the 25B. So I'd push back on his point that we haven't done the math — but the math isn't what matters here, and we don't want to confuse you. Once this stabilizes, we will absolutely come out with a number, but up to now, what we've seen has been encouraging to us.

Dan Leonard

analyst
#41

Jacob, I'd like to hear more about how healthy your diagnostics markets are after the customer listening tour. And given the FDA regulation of LDTs that's coming, does that affect demand for your products, or does it not?

Jacob Thaysen

executive
#42

Yeah. No, I think that's a fair question, and honestly it was something I was keen to get a better handle on when I joined Illumina. As you know, my background is in IBD, and I care deeply about cancer diagnostics — really about fighting cancer — and the way I look at it is, naturally, we serve plenty of clinical customers out there who use the Illumina ecosystem and build their companies on top of it, mainly in the LDT space. Then we have our own offerings in other LDT, but in all areas too, IBD, especially the TSO 500 and the NIPT and other areas where — and if you examine our TSO 500 business, it has grown very rapidly over the recent period; it's above $100 million now, and we anticipate high double-digit growth again this year, and at the moment we see no end to that. So I'm quite bullish about what we can deliver there. And of course, we're conducting a strategic review right now on how that fits within the overall core business strategy. But clearly, we'd also want to compete in that space down the road. There was another — was there a second part to that question?

Joydeep Goswami

executive
#43

How will the regulation affect things?

Jacob Thaysen

executive
#44

Yeah. All right. So the second piece, I believe, concerned the regulation's impact. Naturally, we are watching that extremely closely at the moment; and of course, once again, there is dialogue with our customers, and we're assisting certain customers in making sure they're prepared for it. Our bigger customers are, naturally, able to pursue a single-site PMA, which is helpful for them. Yet there's also a shift that may be occurring in how the different — so certain Class III products are currently viewed as being reclassified down to Class II right now. That remains, in a sense, under consideration. Should that occur, though, it would definitely lower the requirements for getting through clinical trials and so forth as well. So I believe many elements are still in flux. What I can say, though, is that Illumina, in my view, is extremely well placed to support the markets going forward, nearly regardless of where FDA ends up on this one.

Joydeep Goswami

executive
#45

I'd just add this, Jacob: we're basically the only company that has ISO 13485 classification across all our instruments and most of our consumables, even in our REO products, and obviously we have the path to IBD if our customers want it, right? So whichever direction they choose to go in, we're well positioned to serve them.

Kyle Mikson

analyst
#46

Purely from a guidance standpoint, it looks like you probably could have issued a softer outlook than the one you gave back in November. You might have set the bar low. Yet you kept the range as is. Risks are obviously still there. How much visibility or commentary do you actually have? And how much conservatism are you kind of factoring in compared with prior years? And you mentioned some of — what are the biggest swing factors and sort of risks we ought to weigh for 1Q and then the first half versus the second half; and if I could just squeeze in one for you, Joydeep, about 6000 pull-through. The $700,000, $800,000 figure looks like it could be on the aggressive side given the way HiSeq fell off in the years after its 2000 launch. So please just walk us through your thinking on the decline — or the deterioration, I suppose — in 6000 pull-through?

Joydeep Goswami

executive
#47

I'll take the 6000 piece first. That one's maybe easier, right? So keep in mind that when HiSeq was — well, when NovaSeq 6000 came out, we had fewer clinical customers, right? At this point, clinical accounts — roughly half of our consumables revenue comes from clinical customers with validated assays, right, and those customers aren't going to switch platforms in the near term; so the drop in pull-through overall will be more cushioned than what happened with HiSeq. Jacob, would you like to speak to the overall guidance, or should I?

Jacob Thaysen

executive
#48

No, go ahead.

Joydeep Goswami

executive
#49

So overall, I think — look, we've said this many times, right — we view this as a prudent way to approach the whole forecast, right? And although certain markets have shown some indications that macroeconomic conditions could be turning, we haven't built that into our forecast; and the one area where we've taken a pessimistic view is, of course, China, right, where the latest news also appears to back up that point. On the puts and takes, look, a great deal rides on adoption of the X, right? So we're devoting an enormous amount of time to ensuring our X customers can transition fast, can adopt and get going with their assays as quickly as they can. And we'll keep doing that. And of course, should the markets improve, we're very well positioned to gain from any upside. On the other side, additional macroeconomic headwinds that further cut our customers' ability to bring on the X or their spend on consumables would hit us too. Jacob, I don't know whether you'd like to add anything else.

Jacob Thaysen

executive
#50

I think we're in a solid position.

Rachel Vatnsdal Olson

analyst
#51

Let me return to your answer to Patrick's earlier question. You mentioned that gross margin was lighter in 4Q due to a consumables mix shift from 6000 to the X. Could you walk us through that dynamic in more detail? Is it just that the Xs are ramping, so there's less volume leverage at the moment? Or is there something structural in which X consumables carry lower margins? And how should we think about that consumables mix affecting gross margin through '24 as well?

Joydeep Goswami

executive
#52

Yes. To begin with the straightforward piece: no — we've said all along that we built the X and X consumables so that, once at scale, we'd anticipate margins similar to X consumables at scale. What you're observing, naturally, is that during the early adoption period, consumables margins come in lower. We haven't yet scaled up completely. As we progress through '24, you'll see that more or less return to normal. Then, heading into '24, overall gross margins are going to be — are going to depend on several factors, correct? So first, we'll see a modest gain from this lower placement of instruments. We've mentioned before that a modest decrease is what we anticipate there. A greater share of consumables should push gross margin higher. On top of that, we'll gain from some improvement tied to everything we've done to make COGS more productive. Those two factors are the biggest contributors to lifting our gross margins by the time 2024 arrives.

Sallilyn Schwartz

executive
#53

We appreciate your being with us today. Just a note that a replay of this call can be found in the Investors section of our website. That brings our call to a close, and we hope to see you at the conferences and other events coming up.

Operator

operator
#54

Thanks. That brings today’s conference to a close. We appreciate your participation. Have a great day.

Read the full transcript via the API

You're viewing the first half of this call. Get the complete Illumina, Inc. transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.

Get the API View API docs →

This call discussed

For developers and AI pipelines

Programmatic access to Illumina, Inc. earnings transcripts and 132,000+ others is available through the EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments, full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.

More tools for stock research

OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in Illumina, Inc. or any ticker on your watchlist.

StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.